A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours-Reference-Cited by-同舟云学术

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumours

Published:2014-10-07 Issue:10 Volume:111 Page:1932-1944
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Brana I,Berger R,Golan T,Haluska P,Edenfield J,Fiorica J,Stephenson J,Martin L P,Westin S,Hanjani P,Jones M B,Almhanna K,Wenham R M,Sullivan D M,Dalton W S,Gunchenko A,Cheng J D,Siu L L,Gray J E

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2014497.pdf

Reference58 articles.

1. Aster JC, Blacklow SC (2012) Targeting the Notch pathway: twists and turns on the road to rational therapeutics. J Clin Oncol 30: 2418–2420.

2. Atzori F, Tabernero J, Cervantes A, Prudkin L, Andreu J, Rodriguez-Braun E, Domingo A, Guijarro J, Gamez C, Rodon J, Di Cosimo S, Brown H, Clark J, Hardwick JS, Beckman RA, Hanley WD, Hsu K, Calvo E, Rosello S, Langdon RB, Baselga J (2011) A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 17: 6304–6312.

3. Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N (2009) Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443–2452.

4. Baserga R, Peruzzi F, Reiss K (2003) The IGF-1 receptor in cancer biology. Int J Cancer 107: 873–877.

5. Becerra C, Salazar R, Garcia-Carbonero R, Thomas AL, Vazquez-Mazon F, Cassidy J, Maughan T, Gallen M, Iveson T, Hixon M, Gualberto A, Yin D, Bergsland EK, Li D (2011) Phase II trial of figitumumab in patients with refractory, metastatic colorectal cancer (mCRC). 2011 ASCO Annual Meeting; 9 June 2011; Chicago, IL, USA, Abstract 3525.

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Therapy Approach to Overcome the Resistance to PI3K Pathway Inhibitors in Gynecological Cancers;Cells;2024-06-19

2. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies;Signal Transduction and Targeted Therapy;2024-05-27

3. Emerging role of MYB transcription factors in cancer drug resistance;Cancer Drug Resistance;2024-04-30

4. Clinical research progress of ridaforolimus (AP23573, MK8668) over the past decade: a systemic review;Frontiers in Pharmacology;2024-03-22

5. IGF-1R targeting in cancer – does sub-cellular localization matter?;Journal of Experimental & Clinical Cancer Research;2023-10-20